Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 5/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
| ▸ | ERN1 | O75460 | 1/20 | 0.31 |
| ▸ | PGR | P06401 | 1/20 | 0.31 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.31 |
| ▸ | VRK1 | Q99986 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3548146 | 0.90 | OPRL1 (0.50) | OPRL1KCNH2ADORA2AADORA2BVRK1 | |
| SCHEMBL3541557 | 0.83 | OPRL1 (0.47) | OPRL1KCNH2ERN1VRK1OPRM1 | |
| SCHEMBL3543476 | 0.81 | ALDH1A1 (0.37) | OPRL1KCNH2ADORA2BPGRNR3C2 | |
| SCHEMBL3539430 | 0.78 | OPRL1 (0.35) | OPRL1KCNH2VRK1 | |
| SCHEMBL3544013 | 0.78 | OPRL1 (0.49) | OPRL1KCNH2VRK1 | |
| SCHEMBL3542829 | 0.72 | BRD9 (0.34) | OPRL1 | |
| SCHEMBL3542671 | 0.70 | OPRL1 (0.36) | OPRL1KCNH2ADORA2AADORA2BPGR | |
| SCHEMBL3541228 | 0.69 | OPRL1 (0.86) | OPRL1KCNH2OPRM1OPRK1 | |
| SCHEMBL3540676 | 0.67 | OPRL1 (0.51) | OPRL1KCNH2PGRNR3C2OPRK1 | |
| SCHEMBL3549443 | 0.66 | OPRL1 (0.43) | OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7829586-B2 | Aryl-substituted nitrogen-containing heterocyclic compounds | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-11-09 | — | — | US | disclosed |
| US-20090275617-A1 | Aryl-Substituted Nitrogen-Containing Heterocyclic Compounds | MSD K.K. (JP) | 2009-11-05 | — | — | US | disclosed |
| EP-1935881-A1 | ARYL-SUBSTITUTED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275617-A1 | Aryl-Substituted Nitrogen-Containing Heterocyclic Compounds | OPRL1, NPSR1, NPBWR1 | OPRL1 1/4885KCNH2 766/4885ADORA2A 412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.